UPDATE: JP Morgan Raises PT On CVS Caremark To $50

JP Morgan has published a research report on CVS Caremark Corporation CVS and has added the company to JP Morgan's Analyst Focus List with a raised price target of $50, up from $43. In the report, JP Morgan writes, "We point to 4 reasons: 1) a return to double-digit PBM EBIT growth in 2012E; 2) a strong 2012E selling season/well positioned for 2013E; 3) well positioned for generics; and 4) strong cash flows for share repurchases to drive EPS upside." JP Morgan maintains its Overweight rating on CVS Caremark, which closed Friday at $36.35.